DBV Technologies Announces Filing of 2025 Half-Year Report
ByAinvest
Tuesday, Jul 29, 2025 5:39 pm ET1min read
DBVT--
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions. The company is currently investigating the use of its proprietary VIASKIN patch technology to address food allergies. VIASKIN is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin, re-educating the immune system to become desensitized to allergens.
The company's food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers and children. The COMFORT Toddlers study, which began enrolling subjects in June 2025, is a safety study specifically for toddlers aged 1-3 years with peanut allergies [3]. The VITESSE study, a Phase 3 trial for children aged 4-7, is expected to provide topline results in Q4 2025 [4].
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and its ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309) [2].
References:
[1] https://www.globenewswire.com/news-release/2025/07/29/3123631/0/en/DBV-Technologies-announces-filing-of-2025-Half-Year-Report-Conditions-for-accessing-or-consulting-the-Report.html
[2] https://www.stocktitan.net/news/DBVT/dbv-technologies-announces-filing-of-2025-half-year-report-80mo5nsh953u.html
[3] https://www.facebook.com/DBVTechnologies/posts/in-case-you-missed-it-comfort-toddlers-is-underway-this-important-safety-study-i/1331881955604791/
[4] https://www.tradingview.com/news/tradingview:0427f758b1622:0-dbv-technologies-s-a-sec-10-q-report/
DBV Technologies has filed its 2025 Half-Year Report with the French market authority, AMF. The report can be accessed on the company's website or the AMF website. DBV is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions. The company is focused on investigating the use of its proprietary VIASKIN patch technology to address food allergies. DBV's food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers and children.
DBV Technologies has filed its 2025 Half-Year Report with the French market authority, AMF [1]. The report is available on the company's website and the AMF website, in French only. Investors can also request a copy via mail or email.DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions. The company is currently investigating the use of its proprietary VIASKIN patch technology to address food allergies. VIASKIN is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin, re-educating the immune system to become desensitized to allergens.
The company's food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers and children. The COMFORT Toddlers study, which began enrolling subjects in June 2025, is a safety study specifically for toddlers aged 1-3 years with peanut allergies [3]. The VITESSE study, a Phase 3 trial for children aged 4-7, is expected to provide topline results in Q4 2025 [4].
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and its ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309) [2].
References:
[1] https://www.globenewswire.com/news-release/2025/07/29/3123631/0/en/DBV-Technologies-announces-filing-of-2025-Half-Year-Report-Conditions-for-accessing-or-consulting-the-Report.html
[2] https://www.stocktitan.net/news/DBVT/dbv-technologies-announces-filing-of-2025-half-year-report-80mo5nsh953u.html
[3] https://www.facebook.com/DBVTechnologies/posts/in-case-you-missed-it-comfort-toddlers-is-underway-this-important-safety-study-i/1331881955604791/
[4] https://www.tradingview.com/news/tradingview:0427f758b1622:0-dbv-technologies-s-a-sec-10-q-report/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet